Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Expert interview on NTDs – part 1 - 11/04/2019 Carsten_Koehler_Profilbild_Tropenkrankheiten_Tuebingen.jpg

    Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg

    More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-carsten-koehler-impulse-aus-baden-wuerttemberg
  • Press release - 26/03/2019

    EUR 3 million in series A for the growth and development of Cytena GmbH

    The High-Tech Gründerfonds (HTGF) and two private investors are convinced of the importance of single-cell isolation for the production of biopharmaceuticals and for genetic analysis in research and diagnostics. EUR 3 million will be invested in the further development of the technology, the expansion of the sales organization and in opening up further applications for Cytena’s single-cell printers.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eur-3-million-in-series-a-for-the-growth-and-development-of-cytena-gmbh
  • Article - 22/03/2019 Prof. Lichter (left) and Prof. Schneeweiss, who run the Translational Breast Cancer Programme in Heidelberg, in the laboratory

    Personalised therapies for treating metastasing breast cancer

    Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
  • Article - 10/01/2019 Cover of the fourth gene technology report.

    Stocktaking and recommendations for action: the BBAW’s fourth gene technology report

    In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…

    https://www.gesundheitsindustrie-bw.de/en/article/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
  • Press release - 03/12/2018

    SpinDiag closes second financing round of EUR 3.0 million (USD 3.4 million) to complete product development of its point-of-care screening system for antibiotic-resistant bacteria

    One year after its seed financing, SpinDiag GmbH closes a second financing round of EUR 3 million (USD 3.4 million) as planned. The financing will enable SpinDiag to complete the product development of its first product for screening for antibiotic-resistant bacteria and to start clinical trials. This will pave the way for regulatory approval in the EU.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/spindiag-closes-second-financing-round-of-eur-30-million-usd-34-million-to-complete-product-development-of-its-point-of-care-scr
  • Company profile - 19/11/2018 The photo shows a monitor with six radiological images.

    CHILI GmbH – teleradiology pioneers

    Teleradiology is the most advanced telemedicine application in Germany. CHILI GmbH from Dossenheim is one of the companies that has contributed to driving the development of teleradiology forward. The company specialises in PACS and teleradiology systems and helps connect clinics and physicians.

    https://www.gesundheitsindustrie-bw.de/en/article/news/chili-gmbh-teleradiology-pioneers
  • Biosensor - 13/11/2018 Schematic showing the workflow that is required for obtaining a test result with paper strip, pipette, darkness and camera. A test result showing circles with different shades of blue and red.

    Rapid medical test for at-home use

    For quite a number of illnesses, patients need to have the concentrations of the medications they are taking and their blood metabolites checked on a regular basis, which can make life rather difficult. Researchers at the Max Planck Institute for Medical Research in Heidelberg have now developed a test based on the firefly enzyme luciferase. This enzyme can be used to quickly and cheaply measure parameters of interest.

    https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-medical-test-for-at-home-use
  • Article - 02/10/2018 Microscope image of a kidney section, marked with yellow circles.

    Artificial intelligence in the life sciences: machines as assistants

    Artificial intelligence is currently one of the most innovative issues, but also one of the most controversial research areas. It already has a firm footing in many areas of our everyday life and often we are not even aware of it. Artificial intelligence has long been an integral part of many processes in research and diagnostics in medicine and the life sciences – and it will be even more widely used in the future.

    https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-intelligence-in-the-life-sciences-machines-as-assistants
  • Industry report 2018 - 27/09/2018 Branchenreport_Gesundheitsindustrie__Zahlen_und_Fakten_fur_Baden-Wurttemberg_Titelseite_U1.jpg

    The healthcare industry – the innovation driver of the 21st century: opportunities and challenges

    BIOPRO Baden-Württemberg’s new industry report entitled "The Healthcare Industry 2018: Facts and Figures for Baden-Württemberg" has just been published in both German and English. The topic neatly dovetails with the state’s political activities. An evaluation of the region carried out on behalf of the Baden-Württemberg government has clearly recognised the importance of the healthcare sector as a driver of innovation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-healthcare-industry-the-innovation-driver-of-the-21st-century
  • Dossier - 28/08/2018 Woman wearing a white lab coat in a laboratory looking at a tube she is holding in her hand.

    With molecular diagnostics to biomarker-based personalised therapy

    Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
  • Article - 14/08/2018 Photo of the developer team (from left to right): Jonas Pfeil, Daniel
Geiger and Tobias Neckernuß. An optical measurement system can be seen on the right-hand side. Photo: Daniel Geiger

    Simple and fast: new optical method for analysing living cells

    The junior researchers Dr. Daniel Geiger, Tobias Neckernuß and Jonas Pfeil from Ulm have developed an innovative method for non-contact real-time analysis of cells and other particles. The analysis involves low data rates and correspondingly little effort. This is what makes the method so attractive for medical applications.

    https://www.gesundheitsindustrie-bw.de/en/article/news/simple-and-fast-new-optical-method-for-analysing-living-cells
  • Expert interview - 08/08/2018 Das Bild zeigt das Brustbild des ALS-Forschers, und Ärztlichen Direktors der Neurologischen Klinik der Uni Ulm, Prof. Albert Ludolph. Der Neurologe ist Sprecher des DZNE-Standorts Ulm.

    Ludolph: diagnosing and treating neurodegenerative disorders

    Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
  • Press release - 20/07/2018

    First closing at SHS: Medical technology investor raises over €90 million for its fifth fund

    SHS Gesellschaft für Beteiligungsmanagement has received capital commitments of over €90 million in its fifth fund's first closing. The fifth generation of SHS funds is also focused on the life sciences and medical technology sector, and thus on the growing global healthcare market with innovative and strong players, especially in Germany and Switzerland.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-closing-at-shs-medical-technology-investor-raises-over-90-million-for-its-fifth-fund
  • Expert interview - 26/06/2018 Photo of Dr. med. Dr. rer. nat. Saskia Biskup.

    Genome analyses: "Germany lags behind dramatically"

    Around 6,000 genetic diseases can be diagnosed using genetic tests. Genetic testing enables the accurate identification of diseases especially when symptoms are unclear, and also allows statements to be made about disease progression. However, restrictive regulations considerably hinder the use of genetic diagnostics. BIOPRO spoke with Dr. Dr. Saskia Biskup, a human genetics specialist and co-founder of the Tübingen-based company CeGaT.

    https://www.gesundheitsindustrie-bw.de/en/article/news/genome-analyses-germany-lags-behind-dramatically
  • Article - 05/04/2018 Translational cancer research is able to bridge the valley of death. The drawing shows a bridge spanning the two valleys of death in medical research - one between preclinical and clinical research and another between the clinical efficacy of drugs as demonstrated by clinical trials and the evidence of real benefits for patients and society.

    Crossing the valley of death with translational cancer research

    It can take many decades before promising research results become therapies that have a positive effect on cancer patients. Most research projects go adrift somewhere between the laboratory and the bedside in the so-called "valley of death". Projects carried out at the DKFZ show that translational cancer research actually works.

    https://www.gesundheitsindustrie-bw.de/en/article/news/crossing-the-valley-of-death-with-translational-cancer-research
  • Big Data - 26/03/2018 Schematic showing how data of a patient from different sources such as imaging and molecular diagnostics along with expert comments are combined and used for making a decision.

    Eliciting reliable information from big data with classifiers and multimodal data fusion

    Prof. Hans A. Kestler knows a great deal about large amounts of data. He heads up the Institute of Medical Systems Biology at the University of Ulm and is constantly inundated with cooperation enquiries from clinicians. On behalf of BIOPRO, Walter Pytlik asked him whether the conditions for using big data more in biomedical research are already largely present.

    https://www.gesundheitsindustrie-bw.de/en/article/news/eliciting-reliable-information-from-big-data-with-classifiers-and-multimodal-data-fusion
  • Big Data - 13/03/2018 Viegas-User-Activity-on-Wikipedia.png

    “More data does not automatically imply more knowledge“

    In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted.

    https://www.gesundheitsindustrie-bw.de/en/article/news/more-data-does-not-automatically-imply-more-knowledge
  • Article - 01/02/2018 The photo shows the dentate gyrus of a rat (part of the hippocampus). The nuclei of the nerve cells that run like a ribbon from the left-hand to the right-hand side of the photo, are stained red; immature, newly formed nerve cells are white.

    Combined test systems to advance the development of drugs for treating Alzheimer’s

    Which substances are suitable for treating neurodegenerative diseases such as Alzheimer's? Due to complex biochemical relationships, testing suitable drug candidates is difficult, especially in the early drug development phase. Many predictive test systems only cover individual aspects. A team from Baden-Württemberg and France is now combining different models to develop a new approach.

    https://www.gesundheitsindustrie-bw.de/en/article/news/combined-test-systems-to-advance-the-development-of-drugs-for-treating-alzheimers
  • Diagnostics - 29/01/2018 The schematic shows a continuum of lipoprotein particles or different size and their division into major classes and subclasses.

    New test for extended blood fat analysis

    Cholesterol is seen as the cause of atherosclerosis, a disease that can lead to heart attacks and strokes. However, it now seems that the way cholesterol is packaged may be even more important than high blood cholesterol levels. Nuclear magnetic resonance (NMR) spectroscopy now allows the high-throughput analysis of such lipid packages.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-test-for-extended-blood-fat-analysis
  • Big Data - 14/12/2017 Schematic showing the potential explanatory power of chance finds.

    Looking at the whole genome raises new questions

    Research laboratories around the world have long focused on studying the whole human genome. It is hoped that knowing the whole human genome will improve diagnostics and enable more specific therapies. Although genome analysis has not yet reached routine clinical application, whole genome sequencing has already raised many ethical and legal issues - for researchers, physicians and patients.

    https://www.gesundheitsindustrie-bw.de/en/article/news/looking-at-the-whole-genome-raises-new-questions
  • Press release - 04/10/2017

    Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

    Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-receives-58-million-in-financing-to-develop-t-cell-receptor-based-immunotherapies
  • Press release - 05/09/2017 PET-Gerat-Uni-Tubingen.jpg

    Cell marking opens up a window into the body

    A new and particularly reliable method for marking cells can simplify research into diseases such as myocardial infarction, diabetes or Alzheimer's and reduce the use of test animals: Scientists from the University of Tübingen have developed a method by which they can target specific cell types in mice and monitor their behavior using positron emission tomography (PET). PET-based cell tracking allows scientists to observe complex life…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cell-marking-opens-up-a-window-into-the-body
  • Article - 28/08/2017 Schematic showing the device and the test carrier.

    SpinDiag GmbH – rapid test makes it difficult for pathogens

    Antibiotic-resistant pathogens are becoming an increasing problem, especially in hospitals. Infected patients must be isolated as soon as possible. However, appropriate methods for testing patients upon admission to hospital and isolating them if necessary are still lacking. A young biotechnology company from Baden-Württemberg called SpinDiag GmbH has developed a cost-effective method for the rapid testing of microbial resistance in normal…

    https://www.gesundheitsindustrie-bw.de/en/article/news/spindiag-gmbh-rapid-test-makes-it-difficult-for-pathogens
  • Article - 14/08/2017 The two company founders in the laboratory holding reaction vessels.

    Saskia Biskup – towards precision medicine

    Therapeutic success can only be achieved when diagnoses are as precise as possible. Nowadays, genetic analyses can make precise diagnoses for many diseases. And thanks to high-throughput technology, results are available to patients very quickly. Dr. Dr. Saskia Biskup recognised the importance of precision medicine many years ago and went on to found CeGaT GmbH, a company that combines human genetics with high-throughput sequencing. Three…

    https://www.gesundheitsindustrie-bw.de/en/article/news/saskia-biskup-towards-precision-medicine
  • Press release - 20/07/2017

    SpinDiag Raises 1.6 Mio. EUR Seed-Capital

    The Freiburg-based startup SpinDiag GmbH recently closed a 1.6 Mio. EUR seed-round with three private investors. The team developed a revolutionary point-of-care screening system for testing patients for antibiotic-resistant bacteria at their admission to hospitals and almost instantly so. The seed-capital will make it feasible to bring SpinDiag’s system from its current laboratory environment to first tests in hospitals.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/spindiag-raises-16-mio-eur-seed-capital

Page 4 / 18

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 18
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search